other material
confidence high
sentiment neutral
materiality 0.55
Quoin reports reversal of QRX003 benefits 4 weeks post-discontinuation in Netherton syndrome study
Quoin Pharmaceuticals, Ltd.
- M-IASI score returned from 3 (12 weeks) to 18 at 4 weeks post-discontinuation, equaling baseline of 18.
- WINRS (itch) worsened from 2 at 12 weeks to 8 post-discontinuation, exceeding baseline of 7.
- IGA regressed from 'Almost Clear' at 12 weeks back to 'Moderate', same as baseline.
- Data from first twice-daily dosed subject shows complete reversal of all clinical improvements after stopping QRX003.